On June 11, 2026 FORUS Therapeutics Inc ("FORUS") reported that it has been acquired by PharmaEssentia Corporation, a global biopharmaceutical company focused on developing innovative therapies for hematology, oncology, and immunology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This milestone builds on the successful collaboration established between FORUS and PharmaEssentia through the Canadian commercialization partnership for ropeginterferon alfa-2b, an investigational treatment currently under review by Health Canada for patients living with polycythemia vera (PV).
As part of PharmaEssentia, FORUS will continue to leverage its established expertise in the Canadian hematology and oncology environment while benefiting from expanded global resources and capabilities. The integration strengthens the combined organization’s ability to support regulatory, medical, market access, and commercial activities across Canada.
FORUS has built a strong reputation for bringing innovative therapies to Canadian patients and we look forward to continuing to do so alongside the Canadian healthcare community. The acquisition recognizes the value of the existing foundational partnership with Karyopharm and looks to create new opportunities to further support patients living with myeloproliferative neoplasms (MPNs) and other hematologic conditions.
"Our team is excited to become part of PharmaEssentia and to continue advancing our shared commitment to the Canadian hematology community," said Kevin Leshuk, Chief Executive Officer of FORUS Therapeutics. "Together, we are well positioned to build on our existing capabilities and support access to innovative treatment options for patients across Canada."
The FORUS team will continue its work with existing healthcare professionals, patient communities, and partners while supporting the advancement of PharmaEssentia’s growing hematology and oncology portfolio in Canada.
This transaction marks an important step in expanding the organization’s long-term presence in Canada and reinforces its commitment to improving outcomes for patients through scientific innovation and collaboration.
(Press release, FORUS Therapeutics, JUN 11, 2026, View Source;utm_medium=rss&utm_campaign=forus-therapeutics-joins-pharmaessentia-to-strengthen-focus-on-hematology-and-oncology-in-canada [SID1234666566])